With the potential to treat multiple conditions and delivered through intravenous methods ... near-term opportunity as a leading psychedelic drug developer. “On behalf of the board and ...
The company is required to submit phase-IV study protocol to the Central Drugs Standard Control Organisation (CDSCO) within the period of three months of grant of market authorization for further ...